AlphaYouTBPH: Grimaud Brett A. discloses securities transactions
By AlphaYouPublished Form 4
Grimaud Brett A.
Reporting filer
Grimaud Brett A. reported Disposition to issuer in Theravance Biopharma, Inc.: 223917 units of Ordinary Shares, dated 2026-09-23. The full Form 4 contains 3 transaction entries.
- Disclosed
- Sep 25, 2026
Reported details
3 entries| Security | Owner | Date | Code | Action | Quantity | Price | Following holdings | Reporting delay | Filed terms and references |
|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Grimaud Brett A. | 2026-09-23 | D | Disposition to issuer | 223917 | Not stated (see footnotes) | 131,251 | 2 days | Filed terms
|
| Ordinary Shares | Grimaud Brett A. | 2026-09-23 | D | Disposition to issuer | 107812 | Not stated (see footnotes) | 23,439 | 2 days | Filed terms
|
| Ordinary Shares | Grimaud Brett A. | 2026-09-23 | D | Disposition to issuer | 23439 | Not stated (see footnotes) | 0 | 2 days | Filed terms
|
Ordinary Shares
- Owner
- Grimaud Brett A.
- Date
- 2026-09-23
- Code
- D
- Action
- Disposition to issuer
- Quantity
- 223917
- Price
- Not stated (see footnotes)
- Following holdings
- 131,251
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Ordinary Shares
- transaction Date: 2026-09-23
- transaction Form Type: 4
- transaction Code: D
- equity Swap Involved: 0
- transaction Shares: 223917
- id: F1
- transaction Acquired Disposed Code: D
- shares Owned Following Transaction: 131251
- direct Or Indirect Ownership: D
- nature Of Ownership:
Ordinary Shares
- Owner
- Grimaud Brett A.
- Date
- 2026-09-23
- Code
- D
- Action
- Disposition to issuer
- Quantity
- 107812
- Price
- Not stated (see footnotes)
- Following holdings
- 23,439
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Ordinary Shares
- transaction Date: 2026-09-23
- transaction Form Type: 4
- transaction Code: D
- equity Swap Involved: 0
- transaction Shares: 107812
- id: F2
- transaction Acquired Disposed Code: D
- shares Owned Following Transaction: 23439
- direct Or Indirect Ownership: D
- nature Of Ownership:
Ordinary Shares
- Owner
- Grimaud Brett A.
- Date
- 2026-09-23
- Code
- D
- Action
- Disposition to issuer
- Quantity
- 23439
- Price
- Not stated (see footnotes)
- Following holdings
- 0
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Ordinary Shares
- transaction Date: 2026-09-23
- transaction Form Type: 4
- transaction Code: D
- equity Swap Involved: 0
- transaction Shares: 23439
- id: F3
- transaction Acquired Disposed Code: D
- shares Owned Following Transaction: 0
- direct Or Indirect Ownership: D
- nature Of Ownership:
Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.
Filing context
- Quantities and prices are shown in the units filed. No trade value is inferred from their product.
- Grimaud Brett A.: SVP, GEN COUNSEL AND SECRETARY.
- F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time.
- F2: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award.
- F3: As of immediately prior to the Effective Time, each award of performance restricted stock units of the Issuer (a "Company PSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled in exchange for the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares with respect to such Company PSU Award that remained outstanding and unreleased as of immediately prior to the Effective Time, plus (iii) one CVR for each Ordinary Share underlying such Company PSU Award.
Original sources
Prepared automatically from public filing data. Report a correction.